Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.11USD
9:00pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.11
Open
$1.12
Day's High
$1.13
Day's Low
$1.11
Volume
13,739
Avg. Vol
67,819
52-wk High
$1.90
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

Scynexis Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp
Wednesday, 24 Jul 2019 

July 24 (Reuters) - SCYNEXIS Inc ::SCYNEXIS ANNOUNCES SPECIAL PROTOCOL ASSESSMENT (SPA) AGREEMENT WITH FDA FOR PHASE 3 STUDY EVALUATING ORAL IBREXAFUNGERP FOR THE PREVENTION OF RECURRENT VULVOVAGINAL CANDIDIASIS (VVC) (CANDLE STUDY).SCYNEXIS INC - SCYNEXIS REAFFIRMS GUIDANCE TO SUBMIT AN INITIAL NEW DRUG APPLICATION (NDA) FOR TREATMENT OF VVC IN SECOND HALF OF 2020.SCYNEXIS INC - SCYNEXIS REAFFIRMS GUIDANCE TO SUBMIT A SUPPLEMENTAL NDA FOR PREVENTION OF RECURRENT VVC IN 2021.SCYNEXIS INC - CANDLE STUDY EXPECTED TO BEGIN ENROLLING PATIENTS WITH RECURRENT VVC, A CONDITION WITH NO FDA-APPROVED THERAPIES, THIS QUARTER.  Full Article

Scynexis Net Loss For 2018 Was $12.5 Mln Or $0.28 Per Share
Thursday, 14 Mar 2019 

March 14 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.SCYNEXIS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $44.2 MILLION AS OF DECEMBER 31, 2018.SCYNEXIS INC - NET LOSS FOR 2018 WAS $12.5 MILLION, OR $0.28 PER SHARE.  Full Article

Scynexis Is Retiring Existing Term Loan Through A Lower-Interest And Longer-Term Convertible Note
Thursday, 7 Mar 2019 

SCYNEXIS Inc ::SCYNEXIS IS RETIRING EXISTING TERM LOAN THROUGH A LOWER-INTEREST AND LONGER-TERM CONVERTIBLE NOTE.SCYNEXIS INC - SALE OF $16.0 MILLION CONVERTIBLE UNSECURED SENIOR NOTE IN A PRIVATE PLACEMENT TO PUISSANCE CAPITAL.SCYNEXIS - RETIREMENT OF EXISTING TERM LOAN WILL STRENGTHEN NEAR-TERM CASH FLOWS & EXTEND CASH RUNWAY PAST AN ANTICIPATED NDA FILING IN H2 OF 2020.  Full Article

Scynexis Provides Year-End Update And Outlines Plans For 2019
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - SCYNEXIS Inc ::SCYNEXIS PROVIDES YEAR-END UPDATE AND OUTLINES PLANS FOR 2019.SCYNEXIS INC - INITIATED VANISH PHASE 3 PROGRAM OF ORAL IBREXAFUNGERP IN ACUTE VVC.SCYNEXIS - VANISH PHASE 3 PROGRAM OF ORAL IBREXAFUNGERP IN ACUTE VVC TOP-LINE DATA EXPECTED IN 1H 2020 WITH POTENTIAL NDA FILING IN 2H 2020.SCYNEXIS INC - INITIATION OF RECURRENT VVC PHASE 3 TRIAL PLANNED FOR 1H 2019.SCYNEXIS INC - RECEIVED NON-DILUTIVE STATE INCENTIVE CASH BENEFIT OF $6.7 MILLION.SCYNEXIS - CO HAS ABOUT $51 MILLION CASH BALANCE AS OF JAN 3, 2019, SUFFICIENT TO ENSURE FULL FUNDING OF VANISH PHASE 3 VVC TRIALS PAST TOP-LINE DATA.SCYNEXIS - CONTINUED ADVANCEMENT OF ORAL IBREXAFUNGERP CLINICAL DEVELOPMENT PROGRAM IN HOSPITAL-BASED INVASIVE FUNGAL INFECTIONS.  Full Article

Scynexis reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 EARNINGS PER SHARE $0.01.Q3 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.ANTICIPATE THAT RESULTS SHOWING SUPERIORITY OF IBREXAFUNGERP OVER PLACEBO WOULD LEAD TO FILING AN NDA IN 2020 FOR TREATMENT OF VVC.SEES 2020 NDA TO BE FOLLOWED BY A SUPPLEMENTAL NDA IN 2021 FOR PREVENTION OF RECURRENT VVC.  Full Article

Scynexis Q2 Loss Per Share $0.23
Thursday, 9 Aug 2018 

SCYNEXIS Inc ::SCYNEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.  Full Article

Scynexis Reports Positive Results From Phase 2B Vulvovaginal Candidiasis Study
Tuesday, 10 Jul 2018 

July 11 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS POSITIVE RESULTS FROM PHASE 2B DOSE-FINDING STUDY OF ORAL SCY-078 IN VULVOVAGINAL CANDIDIASIS.SCYNEXIS INC - CLINICALLY AND MYCOLOGICALLY EFFECTIVE AND WELL-TOLERATED ORAL DOSE OF SCY-078 IDENTIFIED FOR USE IN PHASE 3 REGISTRATION PROGRAM.SCYNEXIS INC - INITIATION OF PHASE 3 REGISTRATION PROGRAM IN VVC PLANNED FOR Q4 OF 2018.SCYNEXIS INC - BELIEVES THAT 600MG DOSE OF SCY-078 IS OPTIMAL DOSE REGIMEN FOR USE IN VVC PHASE 3 REGISTRATION PROGRAM.SCYNEXIS INC - SCY-078 ORAL DOSE REGIMEN OF 600MG COMPARED FAVORABLY TO FLUCONAZOLE REFERENCE ARM IN THIS PATIENT POPULATION.SCYNEXIS INC - ORAL SCY-078 600MG DOSE WAS GENERALLY WELL-TOLERATED.SCYNEXIS INC - ALL FIVE DOSES OF ORAL SCY-078 DEMONSTRATED MEANINGFUL CLINICAL AND MYCOLOGICAL ACTIVITY.  Full Article

Scynexis Q1 Loss Per Share $0.12
Tuesday, 8 May 2018 

May 8 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q1 LOSS PER SHARE $0.12.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Scynexis Inc ::SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.SCYNEXIS INC - SHARES AND WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $1.69 PER SHARE.  Full Article

Scynexis Provides Corporate And SCY-078 Pipeline Update
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article